Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.

Derek J. Jonker, Chiang Li, Gregory M. Coté et al.|Journal of Clinical Oncology|2015

Cited by 4